Sanofi Taps Nestle's Roger as CFO After Swing to Net Loss
By Adria Calatayud
Sanofi named Nestle's Francois-Xavier Roger as its new chief financial officer and reported a swing to a net loss for the fourth quarter despite strong sales of its blockbuster drug Dupixent.
The French pharmaceutical company said Thursday that Roger, who has been CFO at Nestle for more than eight years, will replace Jean-Baptiste Chasseloup de Chatillon, who is stepping down. The change will be effective from April 1.
Net loss for the fourth quarter was 555 million euros ($600.5 million) compared with a profit of EUR3.11 billion for the same period of 2022, Sanofi said. Higher costs and exceptional items hit the company's profitability.
Business operating profit--one of the company's preferred metrics, which strips out exceptional items--fell 5.2% to EUR2.58 billion.
Net sales rose 1.8% to EUR10.92 billion. At constant currency, sales were up 9.3%, with growth in its specialty-care unit driven by continued strength in anti-inflammatory drug Dupixent--jointly developed with Regeneron Pharmaceuticals--and in vaccines.
Analysts expected business operating profit of EUR2.77 billion on sales of EUR11.04 billion, according to estimates provided by the company.
Sanofi reiterated its outlook for 2024.
Write to Adria Calatayud at adria.calatayud@wsj.com
(END) Dow Jones Newswires
February 01, 2024 02:01 ET (07:01 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
What’s Happening in the Markets This Week
-
4 Top Dividend-Paying REIT Stock Picks
-
After Earnings, Is Netflix Stock a Buy, a Sell, or Fairly Valued?
-
P-CAPE: A Better Way for Investors to Estimate Future Returns
-
Which Stocks Have Driven the Stealth Large-Value Rally?
-
Forecasts for Q2 GDP Report Show a Healthy but Slowing Economy
-
5 Stocks to Buy as the Market Rally Broadens
-
4 Top US Travel Stock Picks
-
How Do Interest Rates Affect Stock Market Returns?
-
American Airlines Earnings: Ticket Distribution Misstep Affected Results
-
Going Into Earnings, Is Albemarle Stock a Buy, a Sell, or Fairly Valued?
-
3 Top Cybersecurity Stock Picks for Long-Term Investors
-
AbbVie Earnings: Firm Sees Strong Next-Generation Immunology Drugs Sales
-
Ford Earnings: Warranty Problems on Older Vehicles Slam Results
-
ServiceNow Earnings: Operating on a Higher Plane Within Enterprise Software